AZNAstraZenecaRunning, no new patients
Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer
Endometrial Neoplasms
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 3
- Patients
- 805 (final count)
- Started
- May 5, 2020
- Main results expected
- Jul 8, 2024
- Fully finished
- Apr 1, 2027
- Results posted
- Dec 23, 2025
What counts as success
The trial's main goal(s), called the “primary outcome.”
Progression-free Survival (PFS) According to RECIST 1.1, Based on Investigator Assessments
Measured over: At baseline, every 9 weeks (wks) up to 18 wks, then every 12 wks until objective radiological disease progression. Assessed until 12 Apr 2023 DCO (08 Jul 2024 DCO for China cohort), up to 50 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT04269200 · record last updated 2026-11-05 · checked 2026-11-09 15:47 UTC